Descripción de la empresa
Genenta Science S.p.A. operates as a clinical-stage biotechnology company focused on the development of hematopoietic stem cell gene therapies designed to treat solid tumors within the Italian market. The company's primary strategic asset is Temferon, which is currently advancing through Phase 1/2a clinical trials specifically for the treatment of glioblastoma multiforme. Operating within the healthcare sector and the biotechnology industry, the firm represents an entity dedicated to advancing cellular medicine technologies rather than generating immediate commercial revenue. With a market capitalization of $16.23M and an annual revenue that is not currently reported in the trailing twelve months, the company's scale reflects the typical characteristics of a pre-commercialization biotech venture. The absence of reported revenue in the standard financial reporting period indicates that the company is still in the research and development phase, where capital is primarily consumed by clinical trial expenses and operational overhead rather than sales generation. This market capitalization figure suggests that the market values the company based on its pipeline potential and intellectual property rather than current cash flow performance.
Salud financiera
The company reports a net income of $-6,529,827 over the trailing twelve months, with an EBITDA of $-6,575,658, while the revenue figure for the same period is not available. The significant negative net income relative to the available EBITDA indicates a cost structure heavily weighted toward direct clinical trial costs, regulatory expenses, and research and development activities that exceed operating cash generation. Free cash flow stands at $-4,092,094, which signifies that the company is burning cash to fund its scientific programs and must rely on external financing or existing cash reserves to sustain operations. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, reflecting that the company has not yet achieved commercial product sales to generate a traditional profit structure. On the balance sheet, the company holds $28.15M in cash against $7.60M in debt, resulting in a debt-to-equity ratio of 34.81, which presents a mixed picture of high leverage relative to equity but a net cash position when absolute cash is considered. The current ratio is listed at 14.15, indicating an extremely strong short-term liquidity position where current assets far exceed current liabilities, providing substantial operational flexibility despite the negative cash flow. Return on Equity is -38.0% and Return on Assets is -17.7%, revealing that management effectiveness in generating profit is currently limited by the high costs of clinical development and the lack of revenue streams.
Evaluación de valoración
The trailing twelve-month P/E ratio is not available due to the lack of earnings, while the forward P/E is listed at -1.07, implying that the market is pricing in a continued expectation of negative earnings in the near future. The price-to-book ratio stands at 0.64, indicating that the stock is trading at a discount to its book value, which is common for biotechnology companies with significant intangible assets like clinical trial data that are not fully captured on the balance sheet. The price-to-sales ratio is not available since no sales are being generated, and the EV/EBITDA ratio is 0.66, suggesting a valuation based on enterprise value that accounts for the company's negative earnings and cash position. The 52-week high is $10.00 and the 52-week low is $0.59, meaning the current market price sits at a level that requires calculation relative to this wide range to determine the specific percentage distance from the highs or lows. The beta value is not available, which prevents a direct comparison of price volatility relative to the broader market index using standard statistical measures. These valuation metrics collectively highlight that the stock is priced based on speculative future potential rather than current financial performance or historical earnings stability.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both not available, reflecting the fact that the company has not yet reached a stage of consistent commercial sales or profitability. Since the company does not distribute dividends, the dividend yield is not available and the payout ratio is 0.0%, indicating that the firm retains all of its earnings, or rather its cash reserves, to reinvest into the development of its gene therapy pipeline. This reinvestment strategy is standard for clinical-stage biotechs, as generating income from the Temferon product candidate is contingent upon successful completion of clinical trials and subsequent regulatory approval. The overall growth and income profile is defined by a high-risk, high-reward trajectory where income generation is deferred until the successful commercialization of the company's lead asset, with no current dividend income available to shareholders.